INTRODUCTION
The notion that the human genome and its encoded machinery are sufficient for our evolutionary success has recently been questioned. In fact, humans are vastly overshadowed by their bacterial companions. Literally, trillions of bacterial organisms form unique ecological niches in almost all body surfaces. From the moment we are born, humans are populated with a complex, constantly changing community of bacteria that both helps shape the mucosal immune system and provides essential nutrients [1, 2] . Despite their overwhelming antigenic load, most of these microorganisms have long been ignored as potential determinants in the pathogenesis of human disease. Novel technological tools such as culture-independent 16S ribosomal RNA pyrosequencing, advances in computational biology, and initiatives such as the National Institutes of Health Human Microbiome Project (HMP) have all reenergized this field of study [3] . Microbiome is the term utilized to describe the sum of ecological bacterial communities (and their genes) that populate human skin, oral cavity, airways, gastrointestinal tract, and genitourinary tract. These bacteria and their genomes are classically identified as commensal, symbiotic, or pathogenic; however, the utility of these labels has grown less clear and the a New York University School of Medicine and b interactions between host and bacteria are becoming increasingly complex.
To date, a nearly complete catalog of the diverse microbial communities in the human body has been revealed [4,5 && ]. The largest bacterial burden lies in the intestines, where nearly three pounds of bacteria and over three million bacterial genes outnumber the human host genome 100 times over [6] . The two predominant microbial phyla of the human gut are the Firmicutes, which includes the important Clostridia class, and the Bacteroidetes. Also present but less pervasive are the phyla Proteobacteria, Actinobacteria, Fusobacteria, and Verrucomicrobia [7] . Interestingly, although debated, studies have identified three core human microbial enterotypes [8] that cluster individuals according to the relative abundance of the microbial genera Bacteroides, Prevotella, and Ruminococcus [9 && ]. Despite the advent of genome-wide association studies (GWASs) and intense research into both major histocompatibility complex (MHC) and non-MHC genetic polymorphisms, the causes of most rheumatic diseases remain elusive. Multiple genetic studies have shaped our understanding of rheumatoid arthritis (RA) susceptibility (i.e. shared epitope hypothesis) [10] and continues to elucidate functional pathways [11] ; however, causal evidence is lacking, as illustrated by a relatively low concordance rate in monozygotic twins. Thus, much focus has shifted to the role of environmental factors and gene-environmental interaction in the pathogenesis of rheumatic diseases. This is particularly true for RA because evidence for autoimmunity in the form of circulating anticyclic citrullinated peptide (CCP) antibodies and rheumatoid factor can be found up to a decade before the disease onset [12] . Interestingly, both antibody titers and epitope specificity rise just a few months before synovitis is apparent, and circulating pro-inflammatory cytokines are also elevated during this preclinical phase [13] . Moreover, synovial biopsies and joint MRIs of asymptomatic individuals with circulating anti-CCP fail to demonstrate the signs of tissue damage [14] . Taken together, these data are highly relevant because they suggest that autoimmunity in RA has an extra-articular origin (i.e. outside-in process) and that a 'second hit' is necessary for arthritis development. Among possible nongenetic triggers, the microbiome has been identified as a possible inciting factor. This review will focus on the recent evidence implicating the gut, oral, and lung microbiomes as en('in')vironmental factors in autoimmune arthritis (Fig. 1) .
MICROBIOME AND MURINE MODELS OF INFLAMMATORY ARTHRITIS
The notion that gut microorganisms can modulate extra-intestinal autoimmunity is not novel. As the gut represents the largest reservoir from which the immune system actively samples antigens, it seems plausible that the microbial make-up of a susceptible individual could influence the initiation, progression, and intensity of local and systemic autoimmune disease. Seminal work in animal models conducted more than 3 decades ago have established a relationship between the development of inflammatory arthritis and the presence or absence of certain bacterial genera (Table 1 ). Rat models of adjuvant-induced and streptococcal cell-wallinduced arthritis show protection against the development of arthritis in the presence of mucosal microbes. In both studies, germ-free reared rats showed increased vulnerability to arthritis [15, 16] . In contrast, a germ-free environment (sterile cages devoid of microorganisms) is protective against the development of arthritis in the spontaneous spondyloarthropathy model of HLA-B27 transgenic rats [17] . This may be explained by the recent work showing that misfolded HLA-B27 in lipopolysaccharide-stimulated macrophages resulted in robust increases in proinflammatory cytokines IL-23 and IL-17, along with intestinal inflammation [18] .
KEY POINTS
Animal models of inflammatory arthritis demonstrate the importance of the microbiome in the development of local and systemic autoimmunity.
There is validated evidence that the autoimmune process in RA begins many years before the emergence of clinical synovitis. The source of autoantibodies such as rheumatoid factor and anti-CCP appear to be extraarticular in nature as seropositive individuals without RA have normal synovial tissue.
Mucosal surfaces constantly exposed to bacterial antigens are being studied as possible sites of autoimmunity initiation.
Peridontal disease is strongly linked to RA, and an altered oral microbiome has been identified in patients with early RA. Porphyromonas gingivalis and its enzymatic machinery for peptide citrullination appear to play a role in the pathogenesis.
The community bacterial composition in the gut is altered in mouse models of inflammatory arthritis and in human patients with RA.
Airway inflammation and autoimmunity (i.e., anti-CCP and rheumatoid factor antibodies) appear to be present even at the preclinical phase of disease. Studies of the RA lung microbiome are currently underway.
Additionally, HLA-B27 transgenic rats lack certain populations of dendritic cells important in maintaining tolerance to self-antigen in their mesenteric lymph nodes [19] . Similarly, both the IL-1 receptor antagonist knockout (IL-1RA -/-) and the K/BxN mouse models of arthritis remain healthy in germ-free environments. Gavaging these mice with Lactobacillus and segmented filamentous bacteria (SFB), respectively, is sufficient for the development of autoimmunity and inflammatory arthritis via induction of a robust Th17 response [20, 21] . The ZAP-70 single-point mutation mouse model, SKG, also develops joint inflammation when reared in conventional cages. In these mice, however, lungresiding fungal organisms appear to be responsible, as SKG mice harbor a larger respiratory fungal load and inflammatory arthritis can be induced by the injection of beta-glucans, a component of fungal cell-wall [22] . Most recently, inflammatory arthritis was induced in rats by introducing oral antigens in the setting of mucosal barrier dysfunction [23] . Taken together, these studies reveal a role for the microbiome in various susceptible animal models and validate a mechanistic relationship between microbes, mucosal immunity, and joint inflammation. A recent experiment investigated the microbiome of arthritis-susceptible Ã0401 transgenic mice and arthritis-resistant Ã0402 transgenic mice [24 && ]. The Ã0401 mice microbiome was dominated by Clostridium bacteria and bacterial diversity was not influenced by age or sex. In contrast, the resistant Ã0402 mice were enriched by the Porphyromonadaceae and Bifidobacteria families, and they displayed strong influences of age and sex. Additionally, the susceptible mice demonstrated increased mucosal permeability and an altered TH17 gene transcriptomic profile. These findings suggest the possibility that host genetics may indeed represent a predetermined factor for harboring a unique microbiome profile.
GUT DYSBIOSIS AND RHEUMATOID ARTHRITIS
Linking intestinal dysbiosis (i.e. alteration of the gut microbiome homeostasis) to RA pathogenesis is far from a novel concept. In fact, the toxemic factor hypothesis was originally formulated at the turn of the 20th century. It proposed that the pathological abundance of Gram-negative bacteria in the intestinal canal led to an increase in toxic metabolites that entered the circulation and ultimately promoted joint inflammation. In fact, therapeutic regimens that theoretically target the intestinal flora and the gut-joint axis have been in use since the 1940s (Fig. 1) . Several of them even became diseasemodifying antirheumatic drugs (DMARDs), such as sulfasalazine and minocycline. Since then, however, there have been relatively few studies directly evaluating the gut microbiota in human RA.
In one study [25] , low-throughput 16S hybridization technique (only eight probes included) was used to evaluate the fecal microbiota of patients with newly diagnosed RA. RA patients showed overall fewer bacterial counts when compared with patients with fibromyalgia. A second study investigated the composition of fecal Lactobacillus communities in early RA patients. Using specific Lactobacillus primers, this study [26] revealed a higher diversity of the genera in early disease. Specifically, there were increased levels of Lactobacillus salivarius, Lactobacillus iners, and Lactobacillus ruminis in the RA group compared with controls, and the presence of Lactobacillus mucosae was unique to RA patients.
We have recently observed that the majority of new-onset, DMARD-naïve RA patients carry high levels of Prevotella copri, a unique species that defines the microbial genome of these patients (eLife Journal, manuscript in press). Gut Prevotella, a Gram-negative anaerobe, appears to be relevant in many inflammatory and autoimmune conditions. In addition to being considered as one of the three recently described enterotypes, Prevotella has also been found in patients with inflammatory bowel disease and was sufficient to induce colitis in an inflammasome knockout mouse model (i.e. NLRP6 pathway) [27] . Most recently, Koeth et al. [28 & ] demonstrated that high abundance of gut Prevotella in healthy individuals correlated with increased plasma levels of trimethylamine N-oxide (TMAO), a substance predictive of cardiovascular events in humans. Metabolism by intestinal microbiota of dietary L-carnitine, a compound abundant in red meat, also produced TMAO and accelerated atherosclerosis in mice, but this did not occur if the intestinal microbiota was concurrently suppressed. These findings are relevant because they may partially help explain the higher incidence of cardiovascular disease in some RA patients.
Despite the recent animal and human evidence implicating the intestinal microbiome in RA development, it remains uncertain whether these states of gut dysbiosis represent a causal-causative factor or rather a secondary effect of local and systemic inflammation. Further work is required to better understand the enzymatic and metabolic effects underlying the changes in gut bacterial communities in RA patients.
EVIDENCE FOR THE RHEUMATOID ARTHRITIS-PERIODONTAL DISEASE ASSOCIATION
Periodontal disease is a common polybacterial infection of the gingival tissue [29] . RA and periodontal disease are known to share pathogenic mechanisms and immunologic pathways of bone and tissue destruction. In both diseases, adaptive and innate immune cells promote secretion of pro-inflammatory cytokines [i.e. IL-1, IL-6, and tumor necrosis factor (TNF)] and other degrading substances such as matrix metalloproteinases and reactive oxygen species [30, 31] . Moreover, although proposed more than a century ago, an epidemiologic association between RA and periodontal disease has recently been validated. A number of studies [32,33 & ,34] have now demonstrated an increased incidence and severity of periodontal disease in RA. A recent population-based effort reinforced an association, albeit rather weak, between a prior history of periodontal disease and new-onset RA, suggesting a causal role for periodontal disease in RA pathogenesis [35] . These findings are not universal, however, and a recent study [36] utilizing patient-reported data failed to demonstrate the association. Additional longitudinal studies are therefore needed to establish a role for periodontal disease in RA pathogenesis. Intriguingly, however, treating periodontal disease appears to improve RA severity and concomitantly decrease pro-inflammatory biomarkers of disease activity such as C-reactive protein, erythrocyte sedimentation rate, TNF, and IL-1beta [37, 38] . RA patients with active periodontal disease are also less responsive to anti-TNF-a inhibition, indicating a potential role for the co-treatment of periodontal disease in TNF refractory patients [39] .
Much research has focused on the specific bacteria associated with periodontal disease. The healthy oral microbiome is second in diversity only to the gut and is dominated by the bacterial phyla Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes, and Fusobacteria [40] . Periodontal disease has traditionally been linked to the 'red-complex' bacteria, which include Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia [41] . New technologies, particularly the aforementioned 16S pyrosequencing, have confirmed these results. Meanwhile, other taxa have also been associated with both periodontal disease development and other aggravating environmental risk factors such as cigarette smoking [42,43 & ].
Despite the established knowledge that periodontal disease is actually a polymicrobial disorder, RA research has focused mostly on P. gingivalis. This bacterium is presumably the only known prokaryote with a gene encoding for peptidyl arginine deiminase (PAD), an enzyme that converts arginine residues into citrulline [44, 45] . The citrullination of mucosal protein peptides such as vimentin, keratin, and a-enolase reportedly generates neoepitopes that can then foster loss of immune tolerance and eventually the production of anticitrullinated protein antibodies (ACPAs). ACPAs are the most specific biomarkers for RA to date, are found in 70-80% of patients, and are known to confer worse prognosis [46, 47] . The prevalent hypothesis posits that P. gingivalis (and the humoral response to it) represents an antigenic source for the creation of ACPAs and subsequent progression to RA [30] . This was further validated by the studies showing that P. gingivalis-derived PAD was capable of citrullinating the human fibrinogen and a-enolase isoforms [48] , and that human a-enolase could also induce autoimmunity and inflammatory arthritis in DR4-transgenic mice [49] . Additionally, treatment of periodontal disease can decrease the levels of circulating ACPAs and anti-P. gingivalis antibodies [50] .
Exposure to P. gingivalis has been indirectly assessed serologically in both clinical RA and in individuals considered to be at-risk for RA development (i.e. first-degree relatives, Native Americans, or those with ACPA positivity without synovitis). Anti-P. gingivalis antibodies correlated with the presence of ACPAs in both groups when compared to controls [51,52 && ,53] . Utilizing pyrosequencing to assess the oral microbiome of patients with new-onset, DMARD-naive RA, we showed a direct presence of P. gingivalis in slightly more than half the cohort. The relative abundance of P. gingivalis, although not statistically significant, was two-fold higher in patients with new-onset RA compared with non-RA controls. Most microbial differences, however, could be attributed to the presence of concomitant advanced periodontal disease [54 && ]. The presence of other taxa, such as Anaeroglobus geminatus and Prevotella/Leptotrichia were intriguingly associated with ACPA seropositivity and clinical RA. Overall, the cumulative data argue for a potential involvement of periodontal disease and P. gingivalis in the development of autoimmunity and clinical RA. Additional population and basic investigations are required to elucidate this complex picture involving altered bacterial diversity in periodontal tissues and the consequent microbe-host interactions in the form of local and systemic inflammatory responses.
AIRWAY INFLAMMATION AND RHEUMATOID ARTHRITIS: A ROLE FOR THE MICROBIOME?
The human airways constitute a vast mucosal surface constantly challenged by a high microbialderived antigenic diversity. Similarly to the oral cavity and the intestinal tract, the respiratory mucosa is home to its own characteristic microbiome [55] [56] [57] . Interestingly, cigarette smoking (arguably the best studied environmental risk factor for RA) is not definitively responsible for producing an altered lung microbiome [55, 56, 58] . Although studies found no association between smoking and modified bacterial diversity, Segal et al. [58] did note a correlation between increased airway inflammation and transposition of traditionally supraglottic bacteria into the lungs, particularly with Prevotella and Porphyromonas.
Although there are no reports directly evaluating the lung microbiome in patients with RA, several studies have suggested a possible role in pathogenesis. Chief among those is the evidence that the lung is a site for local citrullination. Cigarette smoking has been shown to generate increased PAD expression and protein citrullination in bronchoalveolar lavage (BAL) cells of smokers without arthritis [59] , and a subset of patients with lung disease in the absence of existing RA test positive for plasma anti-CCP antibodies. Moreover, PAD polymorphisms, such as PADI4, have also been shown to predispose male smokers to RA [60] . This association appears to be cigarette smoking specific as nonsmoking particulate matter (i.e. a measure of air pollution) was not associated with increased risk of progression to RA in asymptomatic seropositive patients [61] .
Recent studies examined early RA patients and at-risk individuals (i.e. autoantibody positive) for the signs of airway abnormalities using highresolution computed tomography [62 && ]. Signs of inflammation, such as bronchial wall thickening, bronchiectasis, and centrilobular opacities, were common in at-risk individuals and were similar to airway abnormalities seen in patients with early RA. In a separate report, anti-CCP antibodies and rheumatoid factor were found in the induced sputa of several patients from the same cohort [63 && ]. Interestingly, enrichment of the lung microbiome with supraglottic taxa (including oral Porphyromonas and Prevotella) was associated with increased airway inflammation. Taken together, these data suggest that the lung may be an early site of autoimmunerelated injury and potentially a site of generation of RA-related autoimmunity, perhaps because of the presence of periodontal tissue-derived pro-inflammatory microbiota. These data suggests that the lungs participate in the citrullination of proteins and consequent generation of autoimmunity. The potential role of periodontal-disease-associated bacteria in inciting those inflammatory responses, perhaps because of microaspiration, has only recently been described and requires further investigation.
CONCLUSION
A growing body of evidence linking the microbiome with RA pathogenesis is now becoming available. Animal models set a solid foundation for linking bacterial antigenicity to the generation of inflammatory arthritis. However, the application of these studies to human populations is complex, and further investigations into bacterial-host mucosal interactions are needed. The microbiome is vast and multiple human body sites are home to a wide diversity of bacterial populations. The periodontal-disease-associated bacteria are the most extensively studied. Strong evidence confirms the ability of P. gingivalis to citrullinate host proteins, but the relevance of this one bacterium is less obvious when assessed in isolation. A polymicrobial effect in periodontal inflammation and RA pathogenesis seems more likely. The gut carries the largest bacterial burden and is the most directly linked to RA when evaluating animal studies. To date, only a handful of human studies have investigated the gut microbiome in RA patients. Results are encouraging, but mechanistic insights to address the causality are still lacking. The notion that the respiratory mucosa could play a role in RA pathogenesis is relatively new. Advanced imaging techniques indicate that airway inflammation and autoimmunity predate joint disease, as they are often present in the preclinical phases of RA. Taken together, in vitro, animal, and human data suggest that host-bacterial interactions may play a role in autoimmunity initiation.
One possibility is that bacteria sharing similar pro-inflammatory properties may serve as triggering factors in various mucosal sites, particularly in genetically predisposed individuals. 'Pan-microbiome' studies will need to be conducted as they may hold an important key to a deeper understanding of RA pathogenesis. The validation of recent findings while studying the microbiome in the various phases of RA (and in different at-risk populations) will be of the utmost importance. Synergistic in-vivo and in-vitro work will also be required to advance our knowledge in this field, which is promising for its discovery potential in biomarker identification and new therapeutic targets.
